TCT Endovascular: Expert Case Reviews – Acute Stroke Interventions

University at Buffalo State University of New York









Acute stroke with atherosclerotic cervical ICA and tandem intracranial occlusion

Adnan H. Siddiqui, MD, PhD, FACS, FAHA Vice-Chairman & Professor of Neurosurgery SUNY University at Buffalo Director, Neurosurgical Stroke Service, Kaleida Health Chief Medical Officer, Jacobs Institute Sept 21, 2018







Disclosure Statement of Financial Interest

Research Grants: Co-investigator: NINDS 1R01NS064592-01A1, Co-investigator: NIBIB 5 R01 EB002873-07, Co-investigator: NIH/NINDS 1R01NS091075, Co-investigator: NIH-NICHHD R01 HD-04483101

Financial Interest: StimMed, Neuro Technology Investors, Cardinal Consultants, Buffalo Technology Partners, Inc., International Medical Distribution Partners, Reist LLC, Synchron, Viseon, Rebound, Serenity, Blink TBI, Cerebrotech, Endostream, Blockade, Imperative Medical, Neurvana, Cognition

Consultant: Cerenovus, Integra, Medtronic, GuidePoint Global Consulting, Penumbra, Stryker, MicroVention, W.L. Gore & Associates, Three Rivers Medical, Inc., Corindus, Inc., Amnis Therapeutics, Ltd., Imperative Care, Cerebrotech, Rapid Medical, Silk Road Medical, Rebound, Endostream, Cognition

National Steering Committees/PI: Penumbra: 3D Separator Trial, COMPASS Trial, INVEST Trial; Covidien (Now Medtronic): SWIFT PRIME and SWIFT DIRECT Trial; MicroVention: FRED Trial, CONFIDENCE Study; LARGE Trial, POSITIVE Trial,

No consulting salary arrangements. All consulting is per project and/or per hour.



Stroke. 2012 Sep;43(9)



Intravenous Thrombolysis and Endovascular Therapy for Acute Ischemic Stroke With Internal Carotid Artery Occlusion

A Systematic Review of Clinical Outcomes

Maxim Mokin, MD, PhD; Tareq Kass-Hout, MD; Omar Kass-Hout, MD, MPH;Travis M. Dumont, MD; Peter Kan, MD, MPH; Kenneth V. Snyder, MD, PhD;L. Nelson Hopkins, MD; Adnan H. Siddiqui, MD, PhD; Elad I. Levy, MD

Table 4. Outcomes From Systemic Intravenous Thrombolysis vs Endovascular Intra-Arterial Treatment in Patients With Cervical Internal Carotid Artery Occlusion

Outcomes	IV Thrombolysis Group (n=338)	Endovascular Group (n=193)	Р	OR (95% CI)	
Favorable outcome, n (%)	89 (26.3%)	84 (43.5%)	< 0.0001	0.46 (0.32-0.68)	
sICH, n (%)	13 (3.9%)	22 (11.4%)	0.0011	0.31 (0.15-0.63)	
Mortality, n (%)	92 (27.2%)	51 (26.4%)	0.85	1.041 (0.7-1.56)	

Cl Indicates confidence interval; IV, intravenous; OR, odds ratio; sICH, symptomatic intracerebral hemorrhage.

In patients with cervical ICA occlusion, there is significantly higher rate of favorable outcomes with endovascular treatment compared to IV thrombolysis alone



MR CLEAN

Control

(N=267)

65.7

55.5-76.4

157 (58.8)

18 (14-22)

4-38

Intervention

(N=233)

65.8

54.5-76.0

135 (57.9)

17 (14-21)

3-30

145/500 with tandem occlusions

ASPECTS — median (interquartile range)¶	9 (7-10)	9 (8–10)
Intracranial arterial occlusion — no./total no. (%)		
Intracranial ICA	1/233 (0.4)	3/266 (1.1)
ICA with involvement of the M1 middle cerebral artery segment	59/233 (25.3)	75/266 (28.2)
M1 middle cerebral artery segment	154/233 (66.1)	165/266 (62.0)
M2 middle cerebral artery segment	18/233 (7.7)	21/266 (7.9)
A1 or A2 anterior cerebral artery segment	1/233 (0.4)	2/266 (0.8)
Extracranial ICA occlusion — no./total no. (%) **	75/233 (32.2)	70/266 (26.3)

💝 tct2018

Characteristic

NIHSS score†

Range

Interquartile range

Median (interquartile range)

Male sex - no. (%)

Age — yr Median

Table 1. Baseline Characteristics of the 500 Patients.*

ESCAPE

Variable				Common C	Odds Ratio (S	95% CI)	
Age							
>80 yr							3.0 (1.3-
≤80 yr							2.7 (1.7-
ASPECTS	1						
8-10							2.6 (1.7
<8	÷				_		2.7 (1.0
Cervical carotid occlusion							
Yes	1					→→	9.6 (2.6
No			-				2.2 (1.4
IV alteplase	1						
Received							2.5 (1.6
Not received	1.						2.6 (1.1
NIHSS score at baseline							
6–19	1						2.6 (1.6
>19		1					2.4 (1.1
Location of occlusion							
ICA with involvement of	the M1 MCA						2.6 (1.2
segment							
M1 MCA segment or all segments	M2 MCA						2.7 (1.7
Time from stroke onset to	randomization						
≤180 min							2.6 (1.5
>180 min	1						2.5 (1.4
Sex							
Male							2.5 (1.4
Female							2.6 (1.5
	0	2	4	6	8	10	
	-		2	5			
	Control Better		Interve	ention Bette	er		

REVASCAT

Subgroup	No. of Patients	Odds Ratio (95% CI)	P Value for Interaction
Age			0.19
<70 yr	121	2.5 (1.3–4.6)	
≥70 yr	85	0.9 (0.4–2.0)	
Baseline NIHSS			0.34
6–16	92	1.5 (0.7–3.1)	
≥17	114	2.0 (1.0-4.0)	
Site of occlusion			0.82
Intracranial ICA	26		
M1	135	1.2 (0.7–2.2)	
Both cervical ICA and TICA	45	4.3 (1.5–12.5)	
or M1 occlusion			
Time to randomization			0.09
≤4.5 hr	135	1.8 (1.0–3.4)	
>4.5 hr	71	1.4 (0.6–3.3)	
Alteplase			0.75
Yes	150	1.4 (0.8–2.6)	
No	56	2.7 (1.0-7.1)	
ASPECTS score			0.76
<8	101	1.4 (0.7–2.9)	
≥8	105	2.2 (1.1–4.4)	

Control Better Thrombectomy Better

Tandem Lesions: Review

Stent-Retriever Thrombectomy for Acute Anterior Ischemic Stroke with Tandem Occlusion: A Systematic Review and Meta-Analysis Rotem Sivan-Hoffmann^{1,2,3} · Benjamin Gory^{1,2} · Xavier Armoiry^{4,9} · Mayank Goyal⁵ · Roberto Riva¹ · Paul Emile Labeyrie¹ · Anne-Claire Lukaszewicz^{2,6,7} · Jean-Jacques Lehot^{2,6,7} · Laurent Derex⁸ · Francis Turjman^{1,2}



Tandem Lesions

- 11 studies
- 237 patients (all underwent stent retriever thrombectomy)
 - 81% recanalization rate
 - 44 % favorable outcomes (mRS ≤ 2)
 - 13 % mortality



Tandem Lesions

- 193 of 237 patients underwent acute carotid stenting
 - 83% recanalization rate
 - 46 % favorable outcomes (mRS ≤ 2)
 - 13 % mortality
 - Symptomatic ICH 4 %



Tandem Lesions

- Thrombectomy has favorable outcomes
- In the acute setting:
 - Do we need TPA in this cohort of patients?
 - Should we stent?
 - Pre or Post Thrombectomy Stenting?
 - Open or closed cell stent?



Buffalo Protocol for Tandem Lesions

- In the acute setting of intracranial LVO and cervical ICA occlusion on initial CTA (arch to vertex):
 - Patient loaded with aspirin and Brillinta in ED
 - tPA administered as per guidelines based on plain CT Head



Antero- vs Retrograde Stenting

Anterograde

- Address the primary/causative lesion
- Prevent distal emboli
- Improve collateral restoration

Retrograde

- Shorter angiographic times
- Revascularize the symptomatic lesion first





Antero- vs Retrograde Stenting

Management of acute ischemic stroke due to tandem occlusion: should endovascular recanalization of the extracranial or intracranial occlusive lesion be done first?

Leonardo Rangel-Castilla, MD,^{1,5,6} Gary B. Rajah, MD,⁶ Hakeem J. Shakir, MD,^{1,5} Hussain Shallwani, MD,^{1,5} Sirin Gandhi, MD,^{4,5} Jason M. Davies, MD, PhD,^{1,2,5} Kenneth V. Snyder, MD, PhD,^{1,4,5,7} Elad I. Levy, MD, MBA,^{1,3,5,7} and Adnan H. Siddiqui, MD, PhD,^{1,3,5,7,8}

Departments of ¹Neurosurgery, ²Biomedical Informatics, ³Radiology, and ⁴Neurology, Jacobs School of Medicine and Biomedical Sciences, and ⁷Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York; ⁵Department of Neurosurgery, Gates Vascular Institute at Kaleida Health; ⁸Jacobs Institute, Buffalo, New York; and ⁶Department of Neurosurgery, Wayne State School of Medicine, Wayne State University, Detroit, Michigan

Noted that proximal stenting followed by distal thrombectomy compares favorably to other series in terms of outcomes and angiographic times.





Buffalo Protocol for Tandem Lesions

- 9 french femoral sheath
- 9 french balloon guide catheter
- 0.014 wire used to cross the lesion under flow arrest
- If unable to cross with 014, 035 soft exchange with quick cross utilized
- Angioplasty and Stenting of cervical ICA under flow arrest followed by aggressive aspiration
- IVUS used in select cases if concern for luminal thrombus dealt with by aspiration or stenting
- Mechanical thrombectomy performed with ADAPT or stent retriever



Conclusions

- Almost 25% of anterior circulation LVO associated with cervical ICA occlusion
- Revascularization highly beneficial
- Unclear which lesion to deal with first
- We stent first thrombectomy second
- Unclear if tPA is beneficial in this cohort
- Dual antiplatelet therapy likely increases risk of ICH







JACOBS

Gates Vascular Institute

Elad Levy, MD Adnan Siddiqui MD PhD Kenneth Snyder MD PhD Jason Davies MD PhD Nick Hopkins M2